AKT1 and cancer: We found that the combination treatment of trametinib with bortezomib prevented trametinib-induced PHLDA1/2 downregulation and the subsequent AKT transactivation in cancer cells, thereby exerting a synergistic potent anti-cancer effect sufficient to induce apoptosis.